$country= Comparative statistics by cancer registry - SurvCan

Comparative statistics by cancer registry

Registry: Comparative statistics by cancer site

Table2a: Number and proportion of cases with complete/incomplete follow-up and median follow-up (in months) by site

(Izmir, Turkey, 1995-1997 cases followed-up until 2003)

Click on cancer site (ICD-10 code) for comparison
Site ICD-10 No. of cases included Complete FUIncomplete FU: loss to FU% with Complete FU at 5 yearsMedian FU (in months)
Alive/deadAt end of FUNo.%% lost to FU: years from diagnosis
No.%<11-33-5>5
C18Colon37126671.710528.311.13.01.312.984.628.2
C19-20Rectum34423267.511232.516.02.92.011.679.124.6
C32Larynx47830864.417035.69.81.71.522.687.064.0
C50Breast132980660.752339.310.92.31.824.385.072.0
C53Cervix24612751.611948.410.63.72.431.783.351.9
C56Ovary23014161.38938.710.91.32.623.985.249.6
C67Urinary bladder56635061.821638.213.32.71.221.082.949.3
C81Hodgkin lymphoma855665.82934.211.85.91.215.381.165.0
C82-85+C96Non-Hodgkin lymphoma34425674.58825.511.63.22.08.783.222.4
C90Multiple myeloma796886.01114.07.61.31.33.889.819.4
C91Lymphoid leukaemia1619961.46238.67.52.51.926.797.831.9
C92-94Myeloid leukaemia14811980.32919.76.84.12.06.887.116.9


Other tables available for this registry:
- Table1: Data quality indices - Proportion (%) of histologically verified and death certificate only cases, number and proportion of included and excluded cases by site (Izmir, Turkey, 1995-1997 cases followed-up until 2003)
- Table2a: Number and proportion of cases with complete/incomplete follow-up and median follow-up (in months) by site (Izmir, Turkey, 1995-1997 cases followed-up until 2003)
- Table3: Comparison of 1-, 3- and 5-year absolute and relative survival and 5-year age-standardized relative survival (ASRS) by site (Izmir, Turkey, 1995-1997 cases followed-up until 2003)
- Table4: Site-wise number of cases, 5-year absolute and relative survival by sex and relative survival by age group (Izmir, Turkey, 1995-1997 cases followed-up until 2003)
- Table5b: Proportion (%) of cases and 5-year absolute survival by extent of disease and site (Izmir, Turkey, 1995-1997)




Registry chapter:


Consult the chapter in Cancer survival in developping countries (Volume II)